These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting the ubiquitin pathway for cancer treatment. Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052 [TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzyme inhibitors and their potential in cancer therapy. Crosas B Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039 [TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Mattern MR; Wu J; Nicholson B Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084 [TBL] [Abstract][Full Text] [Related]
5. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Pal A; Young MA; Donato NJ Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841 [TBL] [Abstract][Full Text] [Related]
6. Molecular pathways: translational potential of deubiquitinases as drug targets. D'Arcy P; Linder S Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788 [TBL] [Abstract][Full Text] [Related]
7. Overview of approaches for screening for ubiquitin ligase inhibitors. Sun Y Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387 [TBL] [Abstract][Full Text] [Related]
8. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Landré V; Rotblat B; Melino S; Bernassola F; Melino G Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759 [TBL] [Abstract][Full Text] [Related]
9. Strategies for the identification of ubiquitin ligase inhibitors. Goldenberg SJ; Marblestone JG; Mattern MR; Nicholson B Biochem Soc Trans; 2010 Feb; 38(Pt 1):132-6. PubMed ID: 20074047 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies within the ubiquitin proteasome system. Eldridge AG; O'Brien T Cell Death Differ; 2010 Jan; 17(1):4-13. PubMed ID: 19557013 [TBL] [Abstract][Full Text] [Related]
12. Targeting ubiquitin specific proteases for drug discovery. Daviet L; Colland F Biochimie; 2008 Feb; 90(2):270-83. PubMed ID: 17961905 [TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of deubiquitinating enzyme inhibitors. Colland F Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048 [TBL] [Abstract][Full Text] [Related]
14. Drug discovery in the ubiquitin-proteasome system. Nalepa G; Rolfe M; Harper JW Nat Rev Drug Discov; 2006 Jul; 5(7):596-613. PubMed ID: 16816840 [TBL] [Abstract][Full Text] [Related]
15. The ubiquitin system, disease, and drug discovery. Petroski MD BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S7. PubMed ID: 19007437 [TBL] [Abstract][Full Text] [Related]
16. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Ruggeri B; Miknyoczki S; Dorsey B; Hui AM Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760 [TBL] [Abstract][Full Text] [Related]
17. Patented small molecule inhibitors in the ubiquitin proteasome system. Guédat P; Colland F BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S14. PubMed ID: 18047738 [TBL] [Abstract][Full Text] [Related]
18. The demographics of the ubiquitin system. Clague MJ; Heride C; Urbé S Trends Cell Biol; 2015 Jul; 25(7):417-26. PubMed ID: 25906909 [TBL] [Abstract][Full Text] [Related]
19. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Soucy TA; Smith PG; Rolfe M Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147 [TBL] [Abstract][Full Text] [Related]
20. Targeting the ubiquitin proteasome system in haematological malignancies. Crawford LJ; Irvine AE Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]